<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719615</url>
  </required_header>
  <id_info>
    <org_study_id>136-08-EP</org_study_id>
    <nct_id>NCT00719615</nct_id>
  </id_info>
  <brief_title>Assess Vitamin D Levels in Those With &amp; Without Thyroid Cancer</brief_title>
  <official_title>The Relationship Between Vitamin D and Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Vitamin D levels in thyroid cancer patients with
      active disease compared with thyroid cancer patients in remission and patients with thyroid
      nodules.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid cancer is the most common endocrine related malignancy, increasing in incidence in
      recent years. There are relatively few, well known factors, both genetic and environmental,
      which predispose to the development of thyroid cancer. Vitamin D deficiency has been
      associated with other cancers, but the association between vitamin D and thyroid cancer is
      unknown. We plan to do a case control, pilot study to evaluate the relationship between
      vitamin D levels and thyroid nodules, thyroid cancer in remission, and active thyroid cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Persons That Are Vitamin D Deficient in the Thyroid Nodule, Thyroid Cancer in Remission, and the Active Thyroid Cancer Groups.</measure>
    <time_frame>Within 12 months of enrollment in thyroid cancer collaborative registry (TCCR) database</time_frame>
    <description>We evaluated serum calcium,creatinine,albumin,and 25-hydroxyvitaminD(25-OH-D)in 42 thyroid nodule, 45 thyroid cancer in remission, &amp; 24 active thyroid cancer patients. We also determined the number and percent of participants in each group that had vitamin D deficiency, defined as 25-OH-D &lt; 30 ng/ml.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">111</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Thyroid Cancer in Remission Group</arm_group_label>
    <description>Thyroid Cancer-Remission Group &amp; use of Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroid Cancer with Active Disease Group</arm_group_label>
    <description>Thyroid Cancer-Active Group &amp; use of Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroid nodule group (no cancer) &amp; Vit D</arm_group_label>
    <description>Thyroid nodule group without cancer and use of Vitamin D</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The Thyroid Tumor and Cancer Collaborative Registry (TCCR) is a thyroid cancer and thyroid
        nodule database at the University of Nebraska Medical Center. The database serves as a
        registry and biospecimen bank for those who wish to participate in multidisciplinary
        research. The database will be accessed to query for individuals with a diagnosis of
        thyroid cancer, both active disease and in remission, as well as a diagnosis of thyroid
        nodules. Those meeting eligibility requirements will then have their registry information
        and stored biospecimens accessed for testing and review.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases: History of Papillary, Follicular, Follicular Variant of Papillary, or Hurthle
             cell thyroid cancer (both active disease and in remission).

          -  Controls: Individuals with a thyroid nodule, matched to cases for age, BMI, season of
             vitamin D measurement.

          -  Participating in University of Nebraska Medical Center Thyroid Tumor and Cancer
             Collaborative Registry database.

        Exclusion Criteria:

          -  Pregnant or breast feeding women

          -  Medullary thyroid cancer

          -  Anaplastic thyroid cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan W Laney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska Medical Center, Department of Internal Medicine, Section of DEM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://seer.cancer.gov/.</url>
    <description>SEER Database.</description>
  </link>
  <link>
    <url>http://obf.cancer.gov/financial/attachments/06Factbk.pdf.</url>
    <description>National Cancer Institute 2006 Handbook, National Cancer Institute, Bethesda, MD. http://</description>
  </link>
  <reference>
    <citation>National Cancer Institute 2006 Handbook, National Cancer Institute, Bethesda, MD. http://obf.cancer.gov/financial/attachments/06Factbk.pdf.</citation>
  </reference>
  <reference>
    <citation>Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF. The role of vitamin D in cancer prevention. Am J Public Health. 2006 Feb;96(2):252-61. Epub 2005 Dec 27. Review.</citation>
    <PMID>16380576</PMID>
  </reference>
  <reference>
    <citation>Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007 Jun;85(6):1586-91. Erratum in: Am J Clin Nutr. 2008 Mar;87(3):794.</citation>
    <PMID>17556697</PMID>
  </reference>
  <reference>
    <citation>Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control. 2000 Oct;11(9):847-52.</citation>
    <PMID>11075874</PMID>
  </reference>
  <reference>
    <citation>Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study. Carcinogenesis. 2008 Jan;29(1):93-9. Epub 2007 Oct 31.</citation>
    <PMID>17974532</PMID>
  </reference>
  <reference>
    <citation>Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM, Feldman D. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):694-702. Epub 2007 Jan 16.</citation>
    <PMID>17229571</PMID>
  </reference>
  <reference>
    <citation>Welsh J. Vitamin D and prevention of breast cancer. Acta Pharmacol Sin. 2007 Sep;28(9):1373-82. Review.</citation>
    <PMID>17723171</PMID>
  </reference>
  <reference>
    <citation>Liu W, Asa SL, Fantus IG, Walfish PG, Ezzat S. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol. 2002 Feb;160(2):511-9.</citation>
    <PMID>11839571</PMID>
  </reference>
  <reference>
    <citation>Dackiw AP, Ezzat S, Huang P, Liu W, Asa SL. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology. 2004 Dec;145(12):5840-6. Epub 2004 Aug 19.</citation>
    <PMID>15319350</PMID>
  </reference>
  <reference>
    <citation>Khadzkou K, Buchwald P, Westin G, Dralle H, Akerstr√∂m G, Hellman P. 25-hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem. 2006 Mar;54(3):355-61. Epub 2005 Nov 28.</citation>
    <PMID>16314444</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <results_first_submitted>January 27, 2010</results_first_submitted>
  <results_first_submitted_qc>March 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 30, 2010</results_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Whitney Goldner, MD</name_title>
    <organization>University of Nebraska Medical Center</organization>
  </responsible_party>
  <keyword>Thyroid Cancer</keyword>
  <keyword>Thyroid Nodules</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Individuals (at University of Nebraska Medical Center)were selected from a thyroid tumor and cancer collaborative registry (TCCR), database &amp; biospecimen bank, started March 2008. We achieved a sample size of 111 subjects with 24 patients with active thyroid cancer, 45 patients with thyroid cancer in remission and 42 patients with thyroid nodules.</recruitment_details>
      <pre_assignment_details>Individuals who had agreed to participate in the TCCR and who had also given a blood sample were included in sequential order.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Thyroid Nodules</title>
        </group>
        <group group_id="P2">
          <title>Thyroid Cancer in Remission</title>
        </group>
        <group group_id="P3">
          <title>Active Thyroid Cancer</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thyroid Nodules</title>
        </group>
        <group group_id="B2">
          <title>Thyroid Cancer in Remission</title>
        </group>
        <group group_id="B3">
          <title>Active Thyroid Cancer</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Persons That Are Vitamin D Deficient in the Thyroid Nodule, Thyroid Cancer in Remission, and the Active Thyroid Cancer Groups.</title>
        <description>We evaluated serum calcium,creatinine,albumin,and 25-hydroxyvitaminD(25-OH-D)in 42 thyroid nodule, 45 thyroid cancer in remission, &amp; 24 active thyroid cancer patients. We also determined the number and percent of participants in each group that had vitamin D deficiency, defined as 25-OH-D &lt; 30 ng/ml.</description>
        <time_frame>Within 12 months of enrollment in thyroid cancer collaborative registry (TCCR) database</time_frame>
        <population>This study is a pilot study to provide preliminary data. Per protocol, we accrued 37% of the sample size needed for a fully powered study. Using the outcome &quot;the proportion of persons with &quot;vitamin D deficiency&quot;, a sample size of 160 subjects (64 nodule, 64 remission, and 32 active) would achieve an 80% power to detect an effect size of 0.25.</population>
        <group_list>
          <group group_id="O1">
            <title>Thyroid Nodules</title>
          </group>
          <group group_id="O2">
            <title>Thyroid Cancer in Remission</title>
          </group>
          <group group_id="O3">
            <title>Active Thyroid Cancer</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Persons That Are Vitamin D Deficient in the Thyroid Nodule, Thyroid Cancer in Remission, and the Active Thyroid Cancer Groups.</title>
          <description>We evaluated serum calcium,creatinine,albumin,and 25-hydroxyvitaminD(25-OH-D)in 42 thyroid nodule, 45 thyroid cancer in remission, &amp; 24 active thyroid cancer patients. We also determined the number and percent of participants in each group that had vitamin D deficiency, defined as 25-OH-D &lt; 30 ng/ml.</description>
          <population>This study is a pilot study to provide preliminary data. Per protocol, we accrued 37% of the sample size needed for a fully powered study. Using the outcome &quot;the proportion of persons with &quot;vitamin D deficiency&quot;, a sample size of 160 subjects (64 nodule, 64 remission, and 32 active) would achieve an 80% power to detect an effect size of 0.25.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Patient characteristics for each group were assessed using descriptive statistics, including medians, range, frequencies, and proportions. Categorical outcomes were compared between the 3 groups using a Fisher's exact test. A logistic regression modeling procedure was used to compare the odds of a low vitamin D levels between patient groups while adjusting for other risk factors: gender, age, BMI, season, and TNM staging.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Only risk factors significant at the 0.10 level in univariate analysis were included in the multivariate model.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>breach of confidentiality</time_frame>
      <desc>This is a study evaluating stored blood from an established biobank. There was no risk to the patient, except the potential breach of confidentiality.</desc>
      <group_list>
        <group group_id="E1">
          <title>Thyroid Nodules</title>
        </group>
        <group group_id="E2">
          <title>Thyroid Cancer in Remission</title>
        </group>
        <group group_id="E3">
          <title>Active Thyroid Cancer</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial limitations include that it was mostly done on Caucasian subjects; the controls were those with thyroid nodules not subjects without any thyroid disease; the sample size was small; &amp; a small number of Vit D assays used different methods.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Whitney S Goldner, MD</name_or_title>
      <organization>University of Nebraska Medical Center</organization>
      <phone>402-559-6205</phone>
      <email>wgoldner@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

